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Access, Watch, and 
Reserve antibiotics in 
India: challenges for 
WHO stewardship
In its most recent Model List of 
Essential Medicines,1 WHO adopted a 
new classification for antibiotics. This 
new model comprises three categories: 
Key Access antibiotics (eg, β-lactam, 
aminoglycoside, and first-generation 
or second-generation cephalosporin 
antibiotics) that “should be widely 
available, affordable and quality-
assured”;1 Watch Group antibiotics 
(including most of the highest priority 
critically important antimicrobials 
for human medicine—eg, macrolides, 
quinolones, glycopeptides, penems, 
and third-generation cephalosporins)2 
recommended only for specific, 
limited indications; and Reserve Group 
antibiotics (eg, fourth-generation 
and fifth-generation cephalosporins, 
aztreonam, polymixins) for situations 
when all alternative antibiotics have 
failed. In alignment with the WHO 
Global Antimicrobial Resistance 
Action Plan adopted by the World 
Health Assembly in May, 2015,3 the 
intention of this new classification 
system for antibiotics is to combat 
rising antimicrobial resistance, 
improve access and clinical outcomes, 
and preserve the effectiveness of 
antibiotics that are a “last resort”.1 
Following this model, WHO anticipates 
that the use of Watch Group and 
Reserve Group antibiotics will be 
drastically reduced.
Reduction in the use of antibiotics 
represents a huge challenge in India, 
which is a major drug producer and has 
some of the highest sales of antibiotics 
globally and highest levels of 
antimicrobial resistance.4 Contributing 
factors to these high sales include 
failures of India’s drug regulatory 
system (which have been identified 
in government reports5), the sale 
of antibiotics without prescription, 
and the proliferation of fixed-dose 
combination (FDC) antibiotics, 
many of which are not approved in 
other countries or by India’s national 
regulator, the Central Drugs Standard 
Control Organization (CDSCO). 
FDCs are formulations comprising 
two or more drugs combined in a 
fixed ratio of doses and available in 
a single dosage form. FDCs that are 
composed of two antimicrobial drugs, 
especially drugs with mismatched 
dosing regimens, are concerning in the 
context of antimicrobial resistance, 
but few data are available on their use 
in low-income and middle-income 
countries.
We analysed6 systemic antibiotic sales 
in India between 2007 and 2012 using 
previously reported methods and data 
sources that captured prescription and 
non-prescription sales and regulatory 
approval status. We investigated 
the formulations that were sold 
and categorised them according to 
whether they were FDCs or single-
drug formulations (SDFs), their WHO 
classification, CDSCO approval status, 
and approval in the UK and USA. We 
excluded antituberculosis and primary 
antiviral or antifungal formulations. 
For FDC antibiotics, we investigated 
sales of formulations composed of 
two antimicrobial drugs. Our findings 
highlight serious hurdles for controlling 
antimicrobial resistance in India. 
In India, total systemic antibiotic 
sales increased by 26% from 2056 
million Units (where a Unit is a strip of 
ten tablets or capsules, or one bottle 
or vial of an oral liquid or injection) in 
2007–08, to 2583 million in 2011–12. 
The increase was due to the growth 
in sales of FDCs, which rose by 38%, 
whereas sales of SDFs increased by 
20%. By 2011–12, FDCs comprised 
34% (872 million Units), and SDFs 
66% (1711 million Units), of total sales 
in India. 
When examined according to 
the new WHO categories, sales of 
FDC antibiotics in India in 2011–12 
consisted of: 499 million Units 
containing Key Access antibiotics, 
367 million Units containing Watch 
Group antibiotics, 3 million Units 
containing Reserve Group antibiotics, 
and 3 million Units containing 
uncategorised antibiotics. Compared 
with 2007–08, Key Access antibiotic 
sales had risen by 20%; however, sales 
of FDCs with Watch Group or Reserve 
Group antibiotics had risen more 
steeply, by 73% and 174%, respectively. 
The FDC antibiotic sales consisted of 
118 different formulations. 75 (64%) 
of these formulations had no record 
of CDSCO approval, only 43 (36%) 
were CDSCO approved, and five 
(4%) were approved by UK or USA 
regulators, or both (ie, ampicillin-
cloxacillin, amoxicillin-clavulanate, 
imipenem-cilastatin, piperacillin-
tazobactam, and trimethoprim-
sulfamethoxazole). 58 (49%) of the 
FDC formulations were composed of 
two antimicrobials; of these, 43 (74%) 
of 58 were unapproved by the CDSCO 
and 27 (46%) included Watch Group 
antibiotics—eg,  ciprofloxacin-
tinidazole, ceftriaxone-vancomycin, 
norfloxacin-metronidazole—and 
sometimes two Watch Group 
antibiotics together—eg, cefixime-
azithromycin. 489 million Units of 
FDCs composed of two antimicrobial 
drugs were sold in 2011–12, but 
270 million Units (55%) of these 
were of unapproved formulations 
even though the sale of unapproved 
new medicines is illegal in India. 
The sale of FDCs containing Reserve 
Group antibiotics consisted entirely 
of CDSCO-approved combinations 
of fourth-generation cephalosporin 
formulations—ie, cefixime-tazobactam 
or cefixime-sulbactam.
In India during 2011–12, 86 different 
SDF antibiotics were available. In 
contrast with FDC antibiotics, most 
SDF antibiotics were approved 
by the CDSCO (80 of 86), in the 
UK (57  of 86), and in the USA 
(75 of 86). Of the 2011–12 sales, 
703 million (41%) of 1711 million 
Units of SDFs sold were Key Access 
antibiotics; 967 million Units (57%) 
were Watch Group antibiotics; 
18 million Units (1%) were Reserve 
Group antibiotics; and 23 million Units 
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(1%) were uncategorised antibiotics. 
Compared with sales in 2007–08, sales 
of Key Access antibiotics had risen 
by 13%, Watch Group by 24%, and 
Reserve Group by 69%. 
These data show the scale of India’s 
task to reduce the use of Watch 
Group and Reserve Group antibiotics 
in accordance with the WHO 
antimicrobial resistance action plan. 
Not only are overall sales of antibiotics 
increasing, but sales of Watch Group 
and Reserve Group antibiotics are 
increasing more rapidly, driven 
predominantly by FDCs that contain 
Watch Group antibiotics. Moreover, 
huge quantities of the FDCs sold are 
unapproved formulations composed 
of two antimicrobial drugs. 
The changes needed to achieve 
the WHO vision of good use and 
stewardship of antibiotics are feasible. 
Obvious practical steps are to ban the 
sale of unapproved FDC antibiotics 
and to enforce existing regulations 
to prevent unapproved and illegal 
drugs reaching the market. The Indian 
Government has been unsuccessful 
on both counts. Although it has 
acknowledged the problems, 
commissioned reports, and banned 
some unapproved FDCs—including 
antibiotics—in 2007 and 2016, the 
bans were challenged and remain 
unresolved in the courts while the 
FDCs in question apparently remain 
on the market. Aside from regulatory 
measures, appropriate changes in 
antibiotic use would be assisted 
by improved access to health care 
to reduce non-prescription sales. 
Additionally, research is needed to 
understand why doctors complicate 
problems by prescribing unapproved 
antibiotic FDCs.
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